CD200 promotes immunosuppression in the pancreatic tumor microenvironment

Fouad Choueiry(The Ohio State University), Thomas A. Mace(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Journal for ImmunoTherapy of Cancer
June 1, 2020
10.1136/jitc-2019-000189
Cited by 99

Related Papers

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
|Gut|2016|540
Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function
|Scientific Reports|2019|69
Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression
|iScience|2023|34
Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma
|Cancers|2021|31
Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer
|Oncotarget|2015|16